Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hydroxysafflor yellow A in preparation of medicament for resisting Alzheimer disease

A technology for Alzheimer's disease and hydroxysafflower, which is applied in the field of pharmaceutical preparations and can solve problems such as Alzheimer's disease that have not yet been seen

Inactive Publication Date: 2013-04-03
GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, HSYA is clinically used as a drug for treating cardiovascular and cerebrovascular diseases, and there is no research report on its application in the prevention and treatment of Alzheimer's Disease (AD)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hydroxysafflor yellow A in preparation of medicament for resisting Alzheimer disease
  • Application of hydroxysafflor yellow A in preparation of medicament for resisting Alzheimer disease
  • Application of hydroxysafflor yellow A in preparation of medicament for resisting Alzheimer disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0068] Example 1 (injection)

[0069] Take 15g of hydroxysafflower yellow pigment A, add 9g of sodium chloride, add water to 1000ml, adjust the pH to 4.5-7.0 with 1mol / ml sodium hydroxide solution, filter, fill the filtrate into a 5ml ampoule, and sterilize at 100°C for 30min , label and package. This product can be injected intravenously or intramuscularly, one bottle each time, once a day, 14 days as a course of treatment, and can be used continuously for 1-2 courses of treatment.

example 2

[0070] Example 2 (lyophilized powder injection)

[0071] Weigh 40g of mannitol, put it in an appropriate container, add 200ml of water for injection, add 0.2g (0.1% w / v) of charcoal for needles, heat to 80°C, stir for 30min, filter through a 0.22um microporous membrane, and use the filtrate for later use.

[0072] Weigh 80g of hydroxysafflower yellow A, add water for injection to 1000ml, stir to completely dissolve hydroxysafflower yellow A. Mix the hydroxysafflower yellow A solution and the mannitol solution, add water for injection to 2000ml, filter with a 0.22um microporous membrane, sub-package, the filling amount is 80mg of hydroxysafflower yellow A per tube, freeze-dry. Vacuum plugging, capping, labeling, and packaging. This product can be injected intravenously. Take one of the above-mentioned hydroxysafflower yellow A for injection and add it to 250ml of normal saline for injection, and slowly intravenously infuse it once a day, 14 days as a course of treatment.

example 3

[0073] Example 3 (tablet)

[0074] Take 20g of hydroxysafflower yellow pigment A, add 48g of lactose, 110g of starch and mix evenly, use 30g of 7% starch slurry as a binder, wet granulate, dry, add 6.24g of magnesium stearate with a granule amount of 3%, mix Uniformly, and then the granules are compressed into 600 tablets with a punching device, which is a tablet for treating senile dementia. The tablet is taken orally, 2-3 tablets each time, 3 times a day, 15-20 days as a course of treatment, can be used continuously for 2-3 courses of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates the application of hydroxysafflor yellow A in the preparation of a medicament for resisting Alzheimer disease. The medicament comprises the hydroxysafflor yellow A and medically acceptable accessories, wherein the hydroxysafflor yellow A is 1-66.7% by mass of the medicament. The hydroxysafflor yellow A which is a compound in the medicament has the effects of significantly improving the survival rate of the Abeta (25-35) damaged PC12 cells, increasing the content of GSH (glutathione) in the model cells, the mitochondrial membrane potential and the ratio of Bcl-2 / Bax and decreasing the content of MDA (malondialdehyde), the level of ROS (reactive oxygen species) in the cells and the formation of DNA (deoxyribonucleic acid) fragments so that the capacity of resisting oxidation of the human body is enhanced, the damage of the Abeta (25-35) to the nerve cells is improved and the purpose of preventing and / or treating Alzheimer disease is achieved by the ways of protecting the functions of mitochondria of the cells, inhibiting the abnormal apoptosis of the cells, removing the free radicals generated by oxidative stress in the human body and inhibiting the lipid peroxidation.

Description

technical field [0001] The invention relates to a pharmaceutical preparation containing organic active ingredients, in particular to a new drug application of Hydroxysafflor yellow A (HSYA). Background technique [0002] Hydroxysafflower yellow A (HSYA) is the main water-soluble pharmacodynamic monomer component of the traditional Chinese herbal medicine safflower (Carthamus tinctorius L.), and it is a compound with a single chalcone glycoside structure. , the molecular formula is C 27 h 32 o 16 , with a molecular weight of 612.53, is a yellow or brownish yellow powder, easily soluble in water and ethanol aqueous solution. [0003] [0004] Modern pharmacological studies have shown that HSYA has a variety of pharmacological activities. Generally speaking, the pharmacological effects reported in the published literature are as follows: [0005] (1) Protective effect on cerebral ischemic injury (Yuan Yumei, Qian Xiaodong, Cao Hengbin. Research progress on the effect of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/351A61P25/28
Inventor 徐洋苏子仁赖小平林志秀冼彦芳陈建南孔松芝谢庆凤
Owner GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com